Résultats positifs de l’analyse de futilité de CHART-1 - ACHAT - OC 64€
Comme attendu la société annonce ce matin les résultats de l’analyse de futilité de l’étude CHART-1. Cette analyse contrôlée par un comité d’experts indépendants (DSMB) considère le bien-fondé de l’étude d’un point de vue de son efficacité et de la sécurité d’emploi. Les données justifient ainsi la poursuite de l’étude « sans modification du protocole ». Les résultats complets sont maintenant attendus pour mi-2016. Suite à ces résultats, nous confirmons notre recommandation à ACHAT.Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.